Details for New Drug Application (NDA): 021204
✉ Email this page to a colleague
The generic ingredient in STARLIX is nateglinide. There are nine drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the nateglinide profile page.
Summary for 021204
| Tradename: | STARLIX |
| Applicant: | Novartis |
| Ingredient: | nateglinide |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 60MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Dec 22, 2000 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 120MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Dec 22, 2000 | TE: | RLD: | Yes | |||||
Expired US Patents for NDA 021204
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novartis | STARLIX | nateglinide | TABLET;ORAL | 021204-002 | Dec 22, 2000 | 6,844,008 | ⤷ Start Trial |
| Novartis | STARLIX | nateglinide | TABLET;ORAL | 021204-001 | Dec 22, 2000 | 5,463,116 | ⤷ Start Trial |
| Novartis | STARLIX | nateglinide | TABLET;ORAL | 021204-002 | Dec 22, 2000 | 6,559,188 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
